Nov. 19, 2019News & Opinions
French drugmaker Servier has acquired blood cancer treatment Pixuvri from US-based CTI BioPharma for an undisclosed sum.
Sep. 04, 2018News & Opinions
Ahead of its acquisition by Japan’s Takeda Pharmaceutical, Ireland-domiciled, London-listed and US-focused Shire has completed the sale of its oncology portfolio with $262 million in annual sales to French drugmaker Servier for $2.4 ...
Apr. 18, 2018News & Opinions
Ireland-based drugs giant Shire is selling its oncology business to France’s Servier in a deal worth $2.4 billion. The sale comes just as Japan’s Takeda Pharmaceutical was reported to be seeking funds and preparing a takeover ...
Feb. 15, 2016News & Opinions
Major UK drugs firm GlaxoSmithKline (GSK) has been fined more than £37 million by the Competition and Markets Authority (CMA) for anti-competitive behavior relating to generic forms of its anti-depressant Seroxat.
Jun. 20, 2013News & Opinions
European antitrust regulators fined nine drugmakers, including Denmark's Lundbeck, a total of €146 million ($195 million) for blocking the supply of a cheaper anti-depressant to the market, the first EU sanction against such deals.
Jun. 03, 2013News & Opinions
A European regulator will fine Denmark's Lundbeck and eight other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said, its first sanction against "pay-for-delay" deals.
Jul. 25, 2012News & Opinions
EU antitrust regulators are to charge French drugmaker Servier and Danish peer Lundbeck in two separate cases this week related to blocking the entry of cheaper generic medicines into the market, three people familiar with the cases said.
Nov. 03, 2011News & Opinions
Oct. 21, 2010News & Opinions
EU antitrust regulators plan to review drug patent settlements struck this year to delay cheaper generics going to market, as part of their crackdown on illegal deals, a senior European Commission official said on Wednesday.
The latest information directly via newsletter.